{"name":"ML Bio Solutions, Inc.","slug":"ml-bio-solutions-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"BBP-418 (ribitol)","genericName":"BBP-418 (ribitol)","slug":"bbp-418-ribitol","indication":"Other","status":"phase_3"},{"name":"BBP-418","genericName":"BBP-418","slug":"bbp-418","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"BBP-418 (ribitol)","genericName":"BBP-418 (ribitol)","slug":"bbp-418-ribitol","phase":"phase_3","mechanism":"BBP-418 is a ribitol-based compound that modulates immune or metabolic pathways, though its precise mechanism remains proprietary.","indications":[],"catalyst":""},{"name":"BBP-418","genericName":"BBP-418","slug":"bbp-418","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxPVXNtYW5VSlBUa1B4UWJJZlFTUFM1VVBzZE5fTXY0NWdRRHY4Ml9WZ1FlRERqLWlxamdGNjEzMnFYR25ibjBNd0pUVllKTWdxaC1Od1NrcHRHUEdqU0didTZBeXZZU1o3MEFWOVhPeU1sQUlTcjZOaWZyczRETlRwdzdTcGZRSUVHeEQ5UmtXVUJ0LW5ZcFg0YTNFTzRDalN5U25WU1BWLTJVWGRPaXlZS1BvOC1XSlg4R3R0aFpVeXNObnVnSEZ2UkhfWXI0NEM5dHJFUUUwdVJBUW4ydnZhaDZobjd1MjdYbFdFRA?oc=5","date":"2026-02-11","type":"pipeline","source":"Citeline News & Insights","summary":"Scrip Asks... What Does 2026 Hold For Biopharma? Part 5: AI And Operational Excellence - Citeline News & Insights","headline":"Scrip Asks... What Does 2026 Hold For Biopharma? Part 5: AI And Operational Excellence - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBZZ0N2SWZldElxYU1XMlVLbTJJcUw5OGxIcnpxMmFwTGY4Y2pmOWJVVXBqZUJqTVltMkJlU1FtVHJzdGl1akdlQVowUjlEdmJfd3dXSlVLc2xkbDdrYzh3?oc=5","date":"2025-11-28","type":"pipeline","source":"Nature","summary":"A fluorescence-off based approach for sensitive determination of bepotastine in pharmaceutical and biological matrices considering human safety aspects: sustainability assessment | Scientific Reports ","headline":"A fluorescence-off based approach for sensitive determination of bepotastine in pharmaceutical and biological matrices c","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQT0UtQnpVdWNZbkJLRmhTUnFqbEx4cFRnckNlYmJDeldBSlVod2NvVjJSakZWX1ptclhaV0Vjd2FtT21WbTZ2NXh3eHFwVHlMNlcyUEhxcHlxMV90THVBTzJiZmk0UnF5cllxM0k0dDBLRFoxUDBxeTc3NEhtN0lEMEpVNmJMQkVmbHQ2QWRpSXY5OEMwSWlhSVlLSjBLM2lLbTMzcE0zbTdqeWxKdnhB?oc=5","date":"2025-10-28","type":"trial","source":"Muscular Dystrophy News","summary":"LGMD2i therapy seen to improve patients' walking ability in trial - Muscular Dystrophy News","headline":"LGMD2i therapy seen to improve patients' walking ability in trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNS1pDeWRxNkpraHIwRWx4aXMxenVtMVhJWHNORXF2ZkN1bHBRM3dGOThDVE1PWFNkNVA3X01ZSXpHelYtYVBIYTRFR1I5WU5kOV9CcDNnVmd3TkdpWl9aY2JYRHc3SmliZTFDRXk5UldYNzlEVDM5dXdLb3FpOTgwOUxIQ1Q2SDh4ZTgxbXEzUElTbHpHNDhHcG9NVFViMkg5ejN4RkY2eVBSUQ?oc=5","date":"2025-10-28","type":"trial","source":"bizjournals.com","summary":"BridgeBio's stock soars after stunning early data against a deadly rare disease - bizjournals.com","headline":"BridgeBio's stock soars after stunning early data against a deadly rare disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNQjN2VUpJQW5EVUhuQmFIR25MNndldmNSUlJKVlU2dVQwWmtRck52SDU5RWNfRzl0Qkx1UjdTeEU3Z0l5ZTl4eTNTdGlOcWJ1OHRBc0w3WDhCQml2TVlhaU1fODZzTnZHTUJObXF4UEJnQXFQZXpOcFAtZ1FxY2hhbQ?oc=5","date":"2025-10-28","type":"deal","source":"BioSpace","summary":"Pharmaron Acquires Biortus in China - BioSpace","headline":"Pharmaron Acquires Biortus in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOczFkX0lVaXExTWs5SDRhLWVvMEZyTkt1c2cyTlNtN1hzQmFvTkw2cUZlY3M5bVJTUXl3bjFGdkZTcllLcElZUHZjcW5pbWxWQTg3dm55cG8ycWVqbXIzRUFmMWpKSmhIVEpQZzRKYU92MXdqZTM1N3lSbV8zYkxQbklxLXV6d3FudU1DVFdZbERwUEl3MkgyVjhVbGM?oc=5","date":"2025-10-27","type":"regulatory","source":"Fierce Biotech","summary":"BridgeBio aces phase 3 rare disease test, clearing path to FDA - Fierce Biotech","headline":"BridgeBio aces phase 3 rare disease test, clearing path to FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQZHpvZEJJd2NTcE1fSF9wcTJCRFprVEx1c0drVGJpZktRcEFydEZjSmM0T1k0dUdBb2M3d3ZOczZWYk9iek9ET2ZuUHppdkl6eUZJZ3Y4WUhXRF9sSGhrcnJsLXlUa2NpR0p2TUhlRTZ2c3YxWWZZbUN6NXJoSFJGLVVpNW5jYzRwaUNV?oc=5","date":"2025-10-27","type":"regulatory","source":"BioPharma Dive","summary":"BridgeBio to seek approval of limb-girdle drug following new study data - BioPharma Dive","headline":"BridgeBio to seek approval of limb-girdle drug following new study data","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOcVVib3FsaURLX09icjJVREFhZm1yanhHTWFsQTY4V1B4UEZCdEVObHdaZzVVYzUxTXo5WWRjdWZ4UmdYUmRkbUFxa0FPSnp2MFNVTmo3YkZoZDlDTlZEcDJkaXI5akd5UU9BYzR5a1hkckJMMEZuak0wQW9yZHBuaU1ZNG1fSndqNEphWFd0RVlVaUx3dXUwOHU2ejNRdDRUdlkxTmRLSHdfeC0yMkhTUlRZcS1kZjJsR2Y3M2tXYWZCYXFFWWhUR1NuRFA4cGxtMFVkMm94SU5QM3V3VXpzZEpVWldRUmFmUldSSlNhc1g0STFtVGNfakJpUlM?oc=5","date":"2025-10-27","type":"trial","source":"GlobeNewswire","summary":"BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study - GlobeNewswire","headline":"BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNNmxCVkUzZjA2YnJUWG5zd28wX1JaUlFjb1pVbjVtcGZpYjU0akNTNnVQbmNtTUdDbmQ1MWViZU1ScnJUd3FFbnhuZW12Y2k5QkVzMTZUZGo3WnJabkNYZXpyYWtvcC1IbkxxU3czTkN4Smx6NEN3TjJpVF9WeGl0YUMxbw?oc=5","date":"2025-10-27","type":"regulatory","source":"statnews.com","summary":"BridgeBio study data on drug for rare form of muscular dystrophy could set up approval - statnews.com","headline":"BridgeBio study data on drug for rare form of muscular dystrophy could set up approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1DRFp4UzJkTzJtcHEwNXZDTnJ3eTFkRkVhMmc0eHJYb1Q2cW5JNTBSckN0OW9tTm5BREVmUzN6bmJ6ZXY1UzVFd3h5Wi1ZOE1fd2Nz?oc=5","date":"2025-09-09","type":"pipeline","source":"FirstWord Pharma","summary":"Sutter Hill's latest startup debuts with $25M to improve linker technology with AI - FirstWord Pharma","headline":"Sutter Hill's latest startup debuts with $25M to improve linker technology with AI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUXphdkxrUy1SZFpRaWJoSHBvYnNrTEpCLWtiS2xRLUJGdUM3NDhFS2lvNXNJTnAxcGdoVW5GbENJbDFRd2swamIzNHQ1bEY2ekh5bUNjNENPcFFhVlJUNk1fd21LaWc2eU5WRGo5TjFWazZCdk5ULWFMSHlDUHlkbFRNSTlkZHBCc0VLZFBIcGx3RHFqWTBuQnZDYk5YOUxpeHNFeE04VEZmajBxWWotLXU4R2lBMm9jbUNXbkI5WEVMeW0tbjNQbQ?oc=5","date":"2025-06-25","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Solution Building: Merck Avoids One-Size-Fits-All Approach to AI and ML - Genetic Engineering and Biotechnology News","headline":"Solution Building: Merck Avoids One-Size-Fits-All Approach to AI and ML","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNTWtYN2x3N2xZUUlqWGxoblJPN0FJZ2I2a2NYaG52bUxQMllCamZ6WmdYdTZXV08zUU5DOWY1WnhVaGJfdFB0Yl9rQldzT2VlN19fWjRYaEFIVGp2ZUpmc01uNDdjSDUtZ056MGdXNHpFMnpycG1pYVR2dUNtSFl5NncxdG5YckhVOVBnb3BMUVpNZ0pIX0lLS3NhanM1T3ROSVBoU1g2NloxUnlZOElvUk5Yd0ZCeWpXQWRRdE12bw?oc=5","date":"2021-09-30","type":"pipeline","source":"Atrium Health","summary":"Daily Dose - How Atrium Health Medical Research is Helping People with Muscular Dystrophy - Atrium Health","headline":"Daily Dose - How Atrium Health Medical Research is Helping People with Muscular Dystrophy","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}